LoRusso, P., Mukohara, T., Sommerhalder, D., Yonemori, K., Hamilton, E. P., Layman, R. M., Kim, S., Im, S., Rugo, H. S., Yamashita, T., Yan, F., Hara, F., Kim, G. M., Wang, S., Kent, S., Liu, L., Skoura, A., Kowalski, K., Li, M., Park, Y. H. (2025). Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1020